Posts Tagged Mundipharma
The delivery of Theresa May’s letter to European Council president Donald Tusk triggering Article 50, and the official start of the UK’s two-year process of negotiating its divorce from the EU, made the choice of this month’s PME cover an easy one.
Inside the issue there’s a great look at the implications of Brexit for pharma, with Nicola Maguire from law firm Cooley LLP rounding up the industry’s areas of concern, Alexa Forbes from Four health Communications asks ‘can UK pharma rise to the post-Brexit challenge’ and greyhealth group’s Paul Hughes looks at the facts (and the alternative facts) of the situation.
Meanwhile, in a series of exclusive interviews with PME, Japanese pharmaceutical companies pull no punches when it comes to what the reassurance they want from the UK on its future in science and innovation. Read the rest of this entry »
The new issue of PME is out this week and available to view online now, ahead of print copies hitting desks in a few days.
Its features include exclusive interviews with senior executives from AstraZeneca and Mundipharma, plus a column from Astellas Pharma Europe’s Alberto Rinon-Caballero on how to make mentoring work.
There’s also room to turn our spotlight on personalised medicines and companion diagnostics (and the uptake challenges therein), the glioblastoma pipeline and, in this month’s Innovation Update, the convergence of drugs and devices. Read the rest of this entry »